Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding: Mechanistic Insights and Research Implications

Study Background and Research Question

The renin-angiotensin system (RAS) is a cornerstone of cardiovascular physiology, tightly regulating blood pressure, fluid balance, and vascular tone. Peptide hormones derived from angiotensinogen, such as Angiotensin II and its shorter fragments, are well-established vasoconstrictors and key mediators of homeostasis. However, the intersection between RAS peptides and viral pathogenesis has only recently come to the fore, particularly in the context of COVID-19. The SARS-CoV-2 virus uses its spike (S) protein to facilitate entry into host cells via multiple receptors, most notably angiotensin-converting enzyme 2 (ACE2), but also alternative molecules such as neuropilin-1 (NRP1) and AXL. Oliveira et al. (2025) set out to investigate whether naturally occurring angiotensin peptides can modulate spike protein interactions with these receptors, potentially influencing viral infectivity and pathogenesis (reference study).

Key Innovation from the Reference Study

The principal innovation of the study lies in its systematic dissection of how both canonical and truncated angiotensin peptides affect SARS-CoV-2 spike protein binding to its host cell receptors. While prior work has primarily focused on ACE2 as the main point of viral entry, this study highlights the importance of alternative receptors, notably AXL, in mediating infection—especially in tissues with low ACE2 expression. By evaluating a panel of naturally occurring angiotensin fragments, the authors reveal that specific peptide structures, including short C- and N-terminal truncations, can significantly enhance spike–AXL binding, thus suggesting a novel mechanistic link between cardiovascular peptide signaling and viral entry pathways.

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to quantify the effect of various angiotensin peptides on the interaction between the SARS-CoV-2 spike protein and its receptors—AXL, ACE2, and NRP1. The experimental design featured both full-length and truncated angiotensin peptides, including Angiotensin II (1–8), Angiotensin I (1–10), Angiotensin (1–7), Angiotensin (1–6), and a series of N-terminal deletions such as Angiotensin III (2–8), Angiotensin IV (3–8), and Angiotensin (5–7). Additionally, the study included peptide variants with targeted amino acid substitutions and phosphorylation modifications to probe structure-activity relationships. The use of these diverse peptide constructs enabled the team to dissect which specific sequence features drive enhancement of spike–receptor interactions. Quantitative binding data were generated in a controlled in vitro setting, providing comparative potency profiles across the peptide panel (reference).

Core Findings and Why They Matter

The study’s core findings are as follows:

• Angiotensin II (1–8) significantly increases spike protein binding to AXL by approximately two-fold, but does not affect ACE2 or NRP1 binding.
• Truncated peptides, such as Angiotensin (1–7) and Angiotensin (1–6), retain or enhance the capacity to potentiate spike–AXL binding, matching Angiotensin II’s effect.
• N-terminal deletions, including Angiotensin IV (3–8), Angiotensin (2–8), and Angiotensin (5–7)—the H2N-Ile-His-Pro-OH peptide—exhibit even greater enhancement, with Angiotensin IV producing a 2.7-fold increase in spike–AXL binding.
• Certain chemical modifications, such as replacing tyrosine with valine at position 4 or phosphorylating tyrosine, further amplify this effect.
• Among the tested peptides, only Angiotensin IV also increased spike binding to ACE2 and NRP1, indicating a unique broadening of receptor engagement.

These findings highlight a previously unappreciated role for RAS-derived peptides in modulating viral entry mechanisms. The data support the hypothesis that the RAS may contribute to the pathogenesis of COVID-19 not only through its classical cardiovascular effects but also by facilitating viral access to host cells via alternative receptors. This mechanistic link has direct implications for both cardiovascular and infectious disease research, especially in the context of hypertension, where angiotensin peptide levels may be dysregulated (Internal resource).

Comparison with Existing Internal Articles

Several recent reviews and workflow articles have examined the role of Angiotensin 1/2 (5-7) and related peptides in both cardiovascular and viral research contexts. For example, "Angiotensin 1/2 (5-7): Workflow Advances in RAS and Viral Models" discusses practical strategies for using high-purity peptides in experimental systems bridging blood pressure regulation and viral pathogenesis. Meanwhile, "Angiotensin 1/2 (5-7): Charting a New Era in Renin-Angiotensin Research" offers a mechanistic overview of the H2N-Ile-His-Pro-OH peptide as both a vasoconstrictor and emerging modulator in SARS-CoV-2 research, echoing the reference study’s cross-domain insights. Collectively, these articles corroborate the reference study’s findings, underscoring the translational significance of short angiotensin fragments in both cardiovascular and infectious disease models. The present study adds mechanistic depth by directly quantifying how these peptides enhance spike–AXL interactions, offering a workflow-relevant rationale for including peptides like Angiotensin 1/2 (5-7) in experimental protocols.

Limitations and Transferability

While the antibody-based binding assays employed offer robust quantification of spike–receptor interactions, several limitations warrant consideration. The experiments were conducted in vitro, which may not fully capture the complexity of peptide dynamics or receptor expression patterns in vivo. The study does not directly address whether enhanced spike–AXL binding translates to increased viral infectivity or altered disease severity in animal or clinical models. Additionally, the physiological concentrations of angiotensin fragments in relevant tissues during infection remain to be determined. Transferability to translational or therapeutic applications will depend on further validation in complex biological systems, including infection models and patient cohorts. These limitations are acknowledged in the reference and parallel discussions in complementary internal reviews.

Why this cross-domain matters, maturity, and limitations

The intersection of RAS signaling and viral entry mechanisms represents a compelling translational bridge, with implications for understanding COVID-19 pathogenesis in patients with cardiovascular comorbidities. The maturity of this cross-domain insight is still emerging; while mechanistic data support peptide-mediated enhancement of spike–AXL binding, the downstream effects on infection and disease progression remain to be experimentally clarified. Nonetheless, the study provides a strong rationale for incorporating angiotensin peptide analysis into research on both hypertension and infectious diseases.

Protocol Parameters

• Peptide concentrations: Reference study assays utilized micromolar concentrations of angiotensin peptides for in vitro binding quantification. Researchers should titrate within the 1–100 μM range for similar receptor-binding studies.
• Peptide handling: Short peptides such as Angiotensin 1/2 (5-7) are highly soluble in water (≥50 mg/mL), DMSO (≥36.5 mg/mL), and ethanol (≥50 mg/mL), enabling flexible assay integration as reported in product information.
• Storage: For optimal stability, peptides should be kept as solids at –20°C, with solutions prepared freshly for short-term use.
• Assay selection: Antibody-based competitive binding or ELISA formats are recommended for quantifying spike–receptor interactions, with appropriate negative and positive controls as outlined in the reference study.
• Cross-domain models: When bridging cardiovascular and viral research, consider co-cultures or tissue explants expressing relevant receptors (ACE2, AXL) to better recapitulate physiological context.

Research Support Resources

To experimentally probe the mechanistic roles of short angiotensin peptides, researchers can utilize Angiotensin 1/2 (5-7) (H2N-Ile-His-Pro-OH peptide, SKU A1049), a high-purity, workflow-ready fragment widely adopted in renin-angiotensin system research and emerging infectious disease models. Its solubility profile and validated purity facilitate both biochemical and cell-based assays relevant to the findings of Oliveira et al. (2025). For additional protocol optimization and domain-bridging strategies, consult the internal reviews linked above.